ECM
IOVA icon

Endurant Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Endurant Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-80,455
Closed -$492K – 48
2023
Q1 		$492K Buy
80,455
+9,800
+14% +$67.6K 0.25% 42
2022
Q4 		$451K Buy
+70,655
New +$552K 0.18% 48
2022
Q2 		– Sell
-60,720
Closed -$1.01M – 66
2022
Q1 		$1.01M Buy
60,720
+6,739
+12% +$104K 0.27% 55
2021
Q4 		$1.03M Sell
53,981
-77,117
-59% -$1.7M 0.25% 59
2021
Q3 		$3.23M Sell
131,098
-29,264
-18% -$690K 0.74% 34
2021
Q2 		$4.17M Sell
160,362
-150,287
-48% -$3.91M 1.15% 35
2021
Q1 		$9.84M Buy
310,649
+256,428
+473% +$10.6M 2.56% 14
2020
Q4 		$2.52M Buy
+54,221
New +$2.15M 0.91% 36
2020
Q2 		– Sell
-20,207
Closed -$605K – 66
2020
Q1 		$605K Sell
20,207
-148,339
-88% -$3.93M 0.27% 42
2019
Q4 		$4.67M Buy
168,546
+82,477
+96% +$1.88M 1.47% 22
2019
Q3 		$1.57M Sell
86,069
-87,169
-50% -$1.93M 0.56% 32
2019
Q2 		$4.25M Buy
+173,238
New +$2.61M 1.67% 26
2019
Q1 		– Sell
-318,185
Closed -$2.82M – 78
2018
Q4 		$2.82M Buy
318,185
+76,016
+31% +$733K 1.49% 22
2018
Q3 		$2.72M Buy
+242,169
New +$3.44M 1.21% 27

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Endurant Capital Management's IOVA Position: Q2 2023 in Review

Endurant Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 80,455 shares — an estimated $492K sold.

Endurant Capital Management first reported a position in IOVA in Q3 2018 and held it in 14 quarters. The position peaked at $9.84M in Q1 2021. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Endurant Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Endurant Capital Management sold 80,455 Iovance Biotherapeutics shares in Q2 2023, an estimated $492K.
  • Endurant Capital Management first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 14 quarters.
  • Endurant Capital Management's Iovance Biotherapeutics position peaked at $9.84M in Q1 2021.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.